Text Size

Long-tErm Follow-uP of antithrombotIc Management Patterns In Acute CORonary Syndrome Patients in Asia (EPICOR ASIA)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01361386
First received: May 23, 2011
Last updated: May 11, 2012
Last verified: May 2012
History of Changes

May 23, 2011
May 11, 2012
June 2011
March 2014   (final data collection date for primary outcome measure)
short- and long-term medication and treatment prescribed by physicians in real-life setting [ Time Frame: up to 3 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01361386 on ClinicalTrials.gov Archive Site
  • clinical outcome (Cardiovascular events) [ Time Frame: up to 3 years ] [ Designated as safety issue: No ]
  • cost of hospitalization [ Time Frame: up to 3 years ] [ Designated as safety issue: No ]
  • quality of life (EQ-5D questionnaire) [ Time Frame: up to 3 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Long-tErm Follow-uP of antithrombotIc Management Patterns In Acute CORonary Syndrome Patients in Asia
Long-Term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients in Asia

The purpose of this study is to describe the short-and long-tern (i.e. up to 2 years following the index event) AMPs in patients hospitalized for an acute coronary syndrome (i.e. STEMI or NSTE-ACS), and to document clinical outcomes, economic aspects and impact on quality of life of these AMPs in a 'real-life' setting.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Asian patients hospitalized for ACS within 48 hours of symptom onset and who have a final diagnosis of unstable angina (UA), STEMI or non-ST-segment elevation myocardial infarction (NSTEMI).
Acute Coronary Syndrome
Not Provided
1
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
13620
March 2014
March 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Written informed consent has been provided.
  • Diagnosis of STEMI, NSTEMI or UA
  • Hospitalization for the first time within 48 hours of onset of symptoms.

Exclusion Criteria:

  • UA, STEMI, NSTEMI precipitated by or as a complication of surgery, trauma, or GI bleeding or post-PCI UA, STEMI and NSTEMI occurring in patients already hospitalized for other reasons.
  • Current participation in a randomised interventional clinical trial.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
China,   India,   Korea, Republic of,   Malaysia,   Singapore,   Thailand,   Vietnam
 
NCT01361386
NIS-CAP-XXX-2011/1
No
AstraZeneca
AstraZeneca
Not Provided
Study Director: Guy Yeoman AstraZeneca
Study Chair: Prof. Huo Yong Peking University 1st Hospital
Study Chair: Jayanti Visvanathan AstraZeneca
AstraZeneca
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP